BioTuesdays
Avivagen

Avivagen in JV for OxC-beta in China

Avivagen (TSX-V:VIV) has signed an agreement with Shaanxi Jintai Mining, a widely diversified Chinese company, to form a joint venture company to commercialize OxC-beta Livestock in China. The JV will initially target...

Aurinia Logo

Aurinia to begin Phase 3 voclosporin trial in Q2

After an end-of-Phase 2 meeting with the FDA, Aurinia Pharmaceuticals (NASDAQ:AUPH) plans to begin a single Phase 3 clinical trial for voclosporin in the treatment of lupus nephritis (LN). Aurinia believes the Phase 3...

Turnstone Biologics

Turnstone Biologics in $41.4-million financing

Closely-held Turnstone Biologics has completed a $41.4-million series B financing led by new investor, OrbiMed, with participation from another new investor, F-Prime Capital Partners, and existing investors, FACIT and...

Titan Pharmaceuticals Logo

Titan’s Probuphine featured at ISAM meeting

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant was featured in three presentations at the International Society of Addiction Medicine (ISAM) annual meeting in Montreal last week. Probuphine, a subdermal implant...

Mati Therapeutics

New U.S. patent expands Mati’s IP portfolio

Closely-held Mati Therapeutics has been granted a U.S. patent covering a method of providing a sustained drug release to an eye using a proprietary punctal plug design placed in the punctum (tear duct) over a treatment...

Dipexium Pharmaceuticals

Dipexium updates availability of Phase 3 data

Dipexium Pharmaceuticals (NASDAQ:DPRX) updated the status of results from two pivotal Phase 3 clinical trials – OneStep-1 and OneStep-2- of its topical antimicrobial peptide, Locilex, for the treatment of diabetic...

Avivagen

Avivagen in OxC-beta pact with UNAHCO

Avivagen (TSX-V:VIV) has agreed to supply OxC-beta Livestock to UNAHCO for sales and distribution in the Republic of the Philippines. OxC-beta has been shown to be effective and economic in replacing the antibiotics...

microbix

Microbix Q4 preliminary revenue up 57%

Microbix Biosystems (TSX:MBX) expects to report revenue in the range of $3.3-million for the fiscal fourth quarter ended Sept. 30, 2016, an increase of 57% from $2.1-million in the year earlier quarter. Fourth quarter...

Profound Medical Logo

Profound Medical in $17.4-million bought deal

Profound Medical (TSX-V:PRN) has entered into an agreement with a syndicate of underwriters, led by GMP Securities, for a bought deal of 15.82 million common shares at a price of $1.10 each for gross proceeds of $17.4...

Titan Pharmaceuticals

Titan’s Probuphine gains more media attention

Titan Pharmaceutical’s (NASDAQ:TTNP) Probuphine six-month implant of sublingual buprenorphine continues to attract widespread media attention for its ability to treat addiction to opioids. Independent TV station, WHDT...

Ocular Therapeutix

Ocular, Regeneron in wet AMD collaboration

Ocular Therapeutix (NASDAQ:OCUL) has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (NASDAQ:REGN) to develop a sustained release formulation of the vascular...

Mateon Therapeutics

Mateon gets U.S. patent for cathepsin inhibition

The U.S. Patent and Trademark Office has issued a patent to Mateon Therapeutics (NASDAQ:MATN) and Baylor University that covers compounds which modulate cathepsin activity, particularly cathepsin L or cathepsin K, and...

Mesoblast Logo

Mesoblast diabetic kidney disease data published

Results of Mesoblast’s (NASDAQ:MESO; ASX:MSB) Phase 2 trial of its allogeneic mesenchymal precursor cell (MPC) product candidate, MPC-300-IV, in patients with diabetic kidney disease have been published in the current...

Dipexium Pharmaceuticals

Dipexium gets SME designation in Europe

Dipexium Pharmaceuticals (NASDAQ:DPRX) has been granted small and medium enterprise (SME) designation by the European Medicines Agency (EMA).  The company recently completed its pivotal Phase 3 clinical trials...